Chemotherapy Supported by Autologous Hematopoietic Stem Cells

Inclusion Criteria: * 18-60 years old; * there are chemotherapy indicators for ovarian cancer; * ovarian cancer diagnosed by histopathology; * recurrent and metastatic ovarian cancer; * the Eastern Cooperative Oncology Group (ECOG) performance status score≤1; * the expected survival time was more than 3 months; * pre-menopausal women (post-menopausal women must have been postmenopausal for at least 12 months to be considered infertile), and the serum pregnancy test results are negative; * all patients must agree to take effective contraceptive measures during the study period and within 6 months after stopping treatment; * the subjects voluntarily participate in this clinical trial sign an informed consent form and are able to complete the study procedures and follow-up examinations; * bone marrow function is good,ability to perform stem cell mobilisation and collection. Exclusion Criteria: * patients with bone marrow disease; * central nervous system or soft meningeal or bone or bone marrow metastases confirmed by imaging or pathology; * patient has severe cardiac insufficiency; * previous history of allogeneic stem cell transplantation or organ transplantation; * patients with active bleeding and autoimmune thrombocytopenic purpura; * patients with chemotherapy contraindications; * positive for human immunodeficiency virus (HIV); * acute or chronic active hepatitis B or hepatitis C infection.